|
Toggle Summary
May 5, 2021
|
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
Management to host conference call WALTHAM, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
|
|
Toggle Summary
March 8, 2021
|
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by Royalty Pharma for an upfront payment of $60 million and up to $95 million in additional payments
|
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
|
|
Toggle Summary
March 1, 2021
|
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
Management to host conference call WALTHAM, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
|
|
Toggle Summary
January 19, 2021
|
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
WALTHAM, Mass. and NEW YORK , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in
|
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
|
|
Toggle Summary
December 1, 2020
|
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
WALTHAM, Mass. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has received official meeting minutes from the
|
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
|
|
Toggle Summary
November 9, 2020
|
Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
WALTHAM, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies
|
Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
|
|
Toggle Summary
November 2, 2020
|
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
WALTHAM, Mass. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the
|
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
|
|
Toggle Summary
October 26, 2020
|
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
Management to host conference call WALTHAM, Mass. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
|
|
Toggle Summary
September 9, 2020
|
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C.
|
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
|
|
Toggle Summary
September 2, 2020
|
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
WALTHAM, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15 th
|
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
|
